BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27807665)

  • 1. A new transgenic mouse model for conditional overexpression of the Polycomb Group protein EZH2.
    Koppens MA; Tanger E; Nacerddine K; Westerman B; Song JY; van Lohuizen M
    Transgenic Res; 2017 Apr; 26(2):187-196. PubMed ID: 27807665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
    Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
    Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
    van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
    Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
    Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
    Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-203 Interplays with Polycomb Repressive Complexes to Regulate the Proliferation of Neural Stem/Progenitor Cells.
    Liu PP; Tang GB; Xu YJ; Zeng YQ; Zhang SF; Du HZ; Teng ZQ; Liu CM
    Stem Cell Reports; 2017 Jul; 9(1):190-202. PubMed ID: 28602614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.
    Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM
    Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
    Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
    Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
    Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
    Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
    Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
    Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
    Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients.
    Wu Z; Wang Q; Wang L; Li G; Liu H; Fan F; Li Z; Li Y; Tu Y
    J Neurol Sci; 2013 Dec; 335(1-2):191-6. PubMed ID: 24139839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
    Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
    Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis.
    Sasaki M; Yamaguchi J; Itatsu K; Ikeda H; Nakanuma Y
    J Pathol; 2008 Jun; 215(2):175-83. PubMed ID: 18393368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
    Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
    Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
    Yonemitsu Y; Imazeki F; Chiba T; Fukai K; Nagai Y; Miyagi S; Arai M; Aoki R; Miyazaki M; Nakatani Y; Iwama A; Yokosuka O
    Hum Pathol; 2009 Sep; 40(9):1304-11. PubMed ID: 19386347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
    Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
    Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
    Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
    Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma.
    Liu DC; Yang ZL
    Pathol Res Pract; 2011 Aug; 207(8):472-8. PubMed ID: 21719208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.